Surgery for palliation and treatment of advanced breast cancer

Surgical Oncology

Volumn 16, Issue 4, 2007, Pages 249-257

  Alvarado, Michael ^a   Ewing, Cheryl A ^a   Elyassnia, Dino ^a   Foster, Robert D ^a   Shelley Hwang, E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DISEASE COURSE; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; MORBIDITY; MORTALITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SURGICAL TECHNIQUE;

BREAST NEOPLASMS; FEMALE; HUMANS; MAMMAPLASTY; MASTECTOMY; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS;

EID: 36549051592     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2007.08.007     Document Type: Review

References (55)

1. Olson J.S. Bathsheba's breast: women, cancer, and history (2002), Johns Hopkins University Press, Baltimore
2. Burstein H.J., Harris L.N., Marcom P.K., Lambert-Falls R., Havlin K., Overmoyer B., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Journal of Clinical Oncology 21 15 (2003) 2889-2895
3. Gori S., Colozza M., Mosconi A.M., Franceschi E., Basurto C., Cherubini R., et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. British Journal of Cancer 90 1 (2004) 36-40
4. Chin P.L., Andersen J.S., Somlo G., Chu D.Z., Schwarz R.E., and Ellenhorn J.D. Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile?. Journal of the American College of Surgeons 190 3 (2000) 304-309
5. Behnam A.B., Nguyen D., Moran S.L., and Serletti J.M. TRAM flap breast reconstruction for patients with advanced breast disease. Annals of Plastic Surgery 50 6 (2003) 567-571
6. Foster R.D., Esserman L.J., Anthony J.P., Hwang E.S., and Do H. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Annals of Surgical Oncology 9 5 (2002) 462-466
7. Foster R.D., Hansen S.L., Esserman L.J., Hwang E.S., Ewing C., Lane K., et al. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. Archives of Surgery 140 2 (2005) 196-198 [discussion 199-200]
8. Parkash S., Srinivasan R., and Ananthakrishnan N. Primary closure of excisional defects of the breast with local flaps: a problem in the treatment of advanced carcinoma of the breast in developing countries. British Journal of Plastic Surgery 34 3 (1981) 291-294
9. Williams R.J., Fryatt I.J., Abbott W.C., and White H. Omental transposition in the treatment of locally advanced and recurrent breast cancer. British Journal of Surgery 76 6 (1989) 559-563
10. Cheung K.L., Willsher P.C., Robertson J.F., Bailie F.B., Daly J.C., and Blamey R.W. Omental transposition flap for gross locally recurrent breast cancer. The Australian and New Zealand Journal of Surgery 67 4 (1997) 185-186
11. Lee S.H., Cheah D.S., and Krishnan M.M. Omental transposition flap and split skin graft for locally advanced breast carcinoma. Singapore Medical Journal 31 3 (1990) 217-220
12. Apffelstaedt J. Indications and complications of latissimus dorsi myocutaneous flaps in oncologic breast surgery. World Journal of Surgery 26 9 (2002) 1088-1093
13. Anthony J.P., and Foster R.D. The reconstruction of complex thoracic wounds: a fleur-de-lys modification of the rectus abdominis myocutaneous flap. Plastic and Reconstructive Surgery 107 5 (2001) 1229-1233
14. Mohamed S.A., Sakr M.F., El-Hammadi H.A., Moussa M.M., and El-Sharaky M.M. The use of the 'TRAM' flap in some oncological problems. International Surgery 85 4 (2000) 347-352
15. Bogossian N., Chaglassian T., Rosenberg P.H., and Moore M.P. External oblique myocutaneous flap coverage of large chest-wall defects following resection of breast tumors. Plastic and Reconstructive Surgery 97 1 (1996) 97-103
16. Deo S.V., Purkayastha J., Shukla N.K., and Asthana S. Myocutaneous versus thoraco-abdominal flap cover for soft tissue defects following surgery for locally advanced and recurrent breast cancer. Journal of Surgical Oncology 83 1 (2003) 31-35
17. Hidalgo D.A., Saldana E.F., and Rusch V.W. Free flap chest wall reconstruction for recurrent breast cancer and radiation ulcers. Annals of Plastic Surgery 30 4 (1993) 375-380
18. Tukiainen E., Popov P., and Asko-Seljavaara S. Microvascular reconstructions of full-thickness oncological chest wall defects. Annals of Surgery 238 6 (2003) 794-801 [discussion 801-2]
19. Sullivan S.R., Truxillo T.M., Mann G.N., and Isik F.F. Utility of the free deep inferior epigastric perforator flap in chest wall reconstruction. The Breast Journal 13 1 (2007) 50-54
20. Retsky M., Bonadonna G., Demicheli R., Folkman J., Hrushesky W., and Valagussa P. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Research 6 4 (2004) R372-R374
21. Dauplat J., Le Bouedec G., Pomel C., and Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Seminars in Surgical Oncology 19 1 (2000) 42-48
22. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. The New England Journal of Medicine 345 23 (2001) 1655-1659
23. Flanigan R.C., and Yonover P.M. The role of resection for patients with renal carcinoma. Current Oncology Reports 3 5 (2001) 424-432
24. Rosen S.A., Buell J.F., Yoshida A., Kazsuba S., Hurst R., Michelassi F., et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be?. Archives of Surgery 135 5 (2000) 530-534 [discussion 534-5]
25. Cook A.D., Single R., and McCahill L.E. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Annals of Surgical Oncology 12 8 (2005) 637-645
26. Aoyagi K., Koufuji K., Yano S., Murakami N., Miyagi M., Takeda J., et al. Long-term survival after gastric cancer with liver metastasis: a report of two cases. Kurume Medical Journal 48 4 (2001) 335-338
27. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology 7 1 (2007) 41-51
28. Pardoll D. Does the immune system see tumors as foreign or self?. Annual Review of Immunology 21 (2003) 807-839
29. Drake C.G., and Pardoll D.M. Tumor immunology-towards a paradigm of reciprocal research. Seminars in Cancer Biology 12 1 (2002) 73-80
30. Sinha P., Clements V.K., Miller S., and Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunology Immunotherapy 54 11 (2005) 1137-1142
31. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clinical Cancer Research 12 14 Part 1 (2006) 4218-4224
32. Benoy I.H., Elst H., Philips M., Wuyts H., Van Dam P., Scharpe S., et al. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer. Clinical Breast Cancer 7 2 (2006) 146-152
33. Wong N.S., Kahn H.J., Zhang L., Oldfield S., Yang L.Y., Marks A., et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Research Treatment 99 1 (2006) 63-69
34. Braun S., and Marth C. Circulating tumor cells in metastatic breast cancer-toward individualized treatment?. New England Journal of Medicine 351 8 (2004) 824-826
35. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine 351 8 (2004) 781-791
36. Feng Y., Sun B., Li X., Zhang L., Niu Y., Xiao C., et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Research Treatment 103 3 (2007) 319-329
37. Van den Eynden G.G., Van Laere S.J., Van der Auwera I., Gilles L., Burn J.L., Colpaert C., et al. Differential expression of hypoxia and (lymph) angiogenesis-related genes at different metastatic sites in breast cancer. Clinical and Experimental Metastasis 24 1 (2007) 13-23
38. Woelfle U., Cloos J., Sauter G., Riethdorf L., Janicke F., van Diest P., et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Research 63 18 (2003) 5679-5684
39. Khan S.A., Stewart A.K., and Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery 132 4 (2002) 620-626 [discussion 626-7]
40. Babiera G.V., Rao R., Feng L., Meric-Bernstam F., Kuerer H.M., Singletary S.E., et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Annals of Surgical Oncology 13 6 (2006) 776-782
41. Rapiti E., Verkooijen H.M., Vlastos G., Fioretta G., Neyroud-Caspar I., Sappino A.P., et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. Journal of Clinical Oncology 24 18 (2006) 2743-2749
42. Gnerlich J., Jeffe D.B., Deshpande A.D., Beers C., Zander C., and Margenthaler J.A. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Annals of Surgical Oncology 14 8 (2007) 2187-2194
43. Giordano S.H., Buzdar A.U., Smith T.L., Kau S.W., Yang Y., and Hortobagyi G.N. Is breast cancer survival improving?. Cancer 100 1 (2004) 44-52
44. Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., and Buzdar A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. Journal of Clinical Oncology 14 8 (1996) 2197-2205
45. Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park) 11 8 Suppl. 8 (1997) 31-33
46. Aapro M.S. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Seminars in Oncology 26 1 Suppl. 3 (1999) 17-21
47. Bathe O.F., Kaklamanos I.G., Moffat F.L., Boggs J., Franceschi D., and Livingstone A.S. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surgical Oncology 8 1 (1999) 35-42
48. Tait C.R., Waterworth A., Loncaster J., Horgan K., and Dodwell D. The oligometastatic state in breast cancer: hypothesis or reality. Breast 14 2 (2005) 87-93
49. Lee Y.T. Breast carcinoma: pattern of metastasis at autopsy. Journal of Surgical Oncology 23 3 (1983) 175-180
50. Elias D., Maisonnette F., Druet-Cabanac M., Ouellet J.F., Guinebretiere J.M., Spielmann M., et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. American Journal of Surgery 185 2 (2003) 158-164
51. Singletary S.E., Walsh G., Vauthey J.N., Curley S., Sawaya R., Weber K.L., et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8 3 (2003) 241-251
52. Friedel G., Pastorino U., Ginsberg R.J., Goldstraw P., Johnston M., Pass H., et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases. European Journal of Cardiothoracic Surgery 22 3 (2002) 335-344
53. Flickinger J.C., Kondziolka D., Lunsford L.D., Coffey R.J., Goodman M.L., Shaw E.G., et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. International Journal of Radiation Oncology, Biology, Physics 28 4 (1994) 797-802
54. Jawahar A., Willis B.K., Smith D.R., Ampil F., Datta R., and Nanda A. Gamma knife radiosurgery for brain metastases: do patients benefit from adjuvant external-beam radiotherapy? An 18-month comparative analysis. Stereotactic and Functional Neurosurgery 79 3-4 (2002) 262-271
55. Surveillance, Epidemiology, and End Results (SEER) Program 〈www.seer.cancer.gov〉 SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.